The Influence of Systemic Inflammation Response Index on Survival Outcomes of Limited-Stage Small-Cell Lung Cancer Patients Treated with Concurrent Chemoradiotherapy

Table 2

Results of univariate and multivariate analyses.

Characteristic	Patients (N)	Median OS (months)	Univariate value	HR	Multivariate value
Age group
<70 years	132	23.3	0.18	1.08	0.29
≥70 years	49	17.7
Gender
Male	154	18.1	0.11	1.06	0.21
Female	27	23.8
Smoking status
Ex-smoker	174	20.5	0.54	1.05	0.69
Current smokers	7	19.5
ECOG-PS
0–1	141	22.4	0.004	1.76	0.026
2	40	15.8
Anemia
Absent	72	23.7	0.028	1.37	0.041
Present	109	17.6
PCI
Yes	139	20.8	0.003	1.93	0.027
No	42	11.8
TRT scheme
HFRT 45 Gy	104 (57.4)	23.4	0.003	1.59	0.017
CFRT 54 Gy	77 (42.6)	15.8
SIRI
<1.93	110	40.5	<0.001	3.02	<0.001
≥1.93	71	14.2

Abbreviations. OS: overall survival; HR: hazard ratio; ECOG-PS, Eastern Cooperative Oncology Group performance status; PCI: prophylactic cranial irradiation; HFRT: hyperfractionated radiotherapy; CFRT: conventionally fractionated radiotherapy; SIRI: systemic immune-inflammation response index.